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Abstract 
OBJECTIVE: To better understand clinician needs and preferences for the display of 
pharmacogenomic (PGx) information in clinical decision support (CDS) tools. 
MATERIALS AND METHODS: We developed a semi-structured interview to collect feedback 
and preferences in six key areas of PGx CDS design, from clinicians who had prior experience 
with live PGx CDS tools.  Eight clinicians from Northwestern Medicine’s (NM) General Internal 
Medicine clinic participated in the study. 
RESULTS: Clinicians expressed a preference for interruptive pop-up alerts during order entry 
that contain brief descriptions of relevant drug-gene interactions, with a clear and specific 
recommended alternative course of action when a medication is contraindicated.  They did not 
wish to see detailed genetic data, instead preferring phenotypic information predicted from the 
genotype.  Nor did they wish to be interrupted when genetic test results do not indicate a change 
in the treatment plan.  Clinicians reported little familiarity with Clinical Pharmacogenetic 
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Implementation Consortium (CPIC) prescribing recommendations but reported trusting 
recommendations of their professional societies and resources like UpToDate.  Analysis of 
unstructured comments concurred with structured results, indicating a general uncertainty among 
participants around how to interpret and apply PGx information in practice. 
DISCUSSION: Results point to several underlying principles that can inform future PGx CDS 
alert designs, including: Be Specific and Actionable; Be Brief; Display Phenotypes not 
Genotypes; Rely on Sources Clinicians Already Trust; and, Be Adaptable to Learning Effects. 
CONCLUSION: This study is part of a broader socio-technical design approach to PGx CDS 
design underway at NM and provides a baseline for future PGx CDS development.  Designs 
based on these results have the potential to improve clinician education and adherence levels, 
and to improve patient outcomes. 
 
Background and Significance 
 Genomic medicine continues to show promise for improving patient outcomes in myriad 
ways, with new discoveries of links between genetics and health regularly appearing in the 
scientific literature.  Certain specific genetic tests have garnered broad public awareness (e.g. the 
BRCA genes[1]) and direct-to-consumer genetic testing is reaching the mainstream.[2] 
Notwithstanding, clinician comfort levels with genetic data and the use of genetic testing remains 
relatively low.[3] [4] Integration of genetic- and genomic-based factors into standard clinical 
practices must be done in a way that benefits both the clinician and the patient, allowing the best 
course of action to be followed with minimal burden and confusion. 
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 Pharmacogenomics (PGx) is among the most promising areas of genomic medicine.  It is 
regularly cited as a means to reduce adverse drug events, avoid ineffective drugs, and optimize 
drug and dose selection more reliably and with less trial-and-error.[5,6] Clinical 
recommendations for the use of PGx in drug prescribing exist but are not yet widely 
implemented.[7]  Clinical decision support (CDS) that delivers PGx information and prescribing 
recommendations at the point of care is one promising way of disseminating this knowledge and 
improving patient care.[8-11] 
 Some PGx CDS implementations have been described in the literature.  Most sites in the 
Electronic Medical Records and Genomics (eMERGE) Network have implemented PGx CDS 
systems.[12,13] Several other organizations have also succeeded in implementing first-
generation PGx CDS systems, both in the United States[14-16] and other countries.[17]  
Institutions implementing PGx CDS tools have taken widely varying approaches – the University 
of Chicago’s Genomic Prescribing System uses a “traffic light” model in a standalone 
system,[18,19] while St. Jude’s PG4KDS system uses traditional pop-up alerts integrated into the 
EHR.[20] Even within the eMERGE network, where institutions collaborate on genomic 
medicine projects, significant variation in PGx CDS alert design made it difficult to aggregate 
results for cross-site analyses.[13]  There is little information regarding which of these designs 
may be the most effective at conveying PGx knowledge to providers and improving care, and 
similarly, little consensus around optimal PGx CDS design. 
 Some studies have begun to examine PGx CDS alerts in an effort to optimize their 
designs, but this work has been too preliminary to drive a consensus on best practices for 
incorporating PGx knowledge into clinician workflows, or for displaying it in a way that is easy 
4 
 
to understand and use by clinicians.[13,20-22] Due to the complexities of genomic medicine, and 
low levels of clinician education and comfort in the field, simpler approaches to PGx CDS 
development—such as design-by-committee processes—may not be effective.[23] Instead, more 
formal socio-technical design approaches that iterate on designs, deeply incorporate user 
workflow needs, and respond to user feedback at multiple phases of development may be more 
effective in creating genuinely useful PGx CDS tools. 
 
Objective 
This study aimed to apply socio-technical design methods to determine actual clinician 
preferences for PGx information at Northwestern Medicine, as a first step towards designing 
better-optimized PGx CDS alerts. This was accomplished through a series of semi-structured 
interviews conducted with clinicians who have real-world experience with a live PGx CDS 
system.  The results of this study can be used to inform future improvements on PGx CDS 
designs.  This study emphasized matching the user’s workflow and information needs through a 
focus on appropriate timing and location for PGx data display, type of information conveyed, 
level of detail, specificity of recommendations, and trusted sources of PGx recommendations. 
 
Materials and Methods 
We developed a semi-structured interview that focused on areas of interest we identified 
after previous phases of NU’s eMERGE-PGx project.[11] We interviewed eight clinicians from 
Northwestern Medicine’s General Internal Medicine (GIM) outpatient clinic.  Each of the 
participants had previous experience with our existing PGx CDS tools.  Existing PGx CDS tools 
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were built using the Best Practice Advisories functionality of the clinic’s EHR (Epic Systems 
Corp., Verona, WI), based on genomic indicators received from an ancillary genomic 
system.[24] As described in detail below, interviews were transcribed and systematically 
analyzed to identify themes and attitudes that could inform the design of improved alerts.  The 
Northwestern IRB approved all aspects of this study. 
Building upon our previous research,[23] we identified six areas of interest for which we 
believed a better understanding could lead to improved alert designs and more positive clinician 
interactions.  We developed an interview guide with a series of structured and open-ended 
questions to probe these areas.  The areas of interest and methods for assessing them are listed in 
Table 1.  All interviews began with a series of questions assessing basic demographics and PGx 
comfort level.  Participants were provided the opportunity to elaborate upon their answers for all 
structured questions, if desired.  The complete interview guide is available in Supplement 1. 
Table 1 - Areas of Interest and Methods of Assessment 
Area of Interest Method of Assessment 
Understanding Workflow 1 open-ended question (based on a model 
workflow diagram) 
Feedback on Existing Tools 3 Yes/No questions 
1 open-ended question 
Appropriate Locations for PGx Information 7 Likert-scale questions (7-point scale) 
Level of Detail and Interruption for Alerts 4 Preference-ranked questions (4 options) 
Types of Information to Display in Alerts 13 Likert-scale questions (7-point scale) 
Trusted Knowledge Sources for PGx 3 Yes/No questions 
3 open-ended questions 
 
 Because we were interested in receiving feedback on the workflows and alerts used in the 
existing PGx CDS tools in place at NM, we limited recruitment to clinicians who had previously 
interacted with those tools in a real-world clinical setting.  Through a query of EHR data 
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available in the Northwestern Medicine Enterprise Data Warehouse (NMEDW), we identified all 
clinicians who had previously recorded an interaction with at least two PGx CDS alerts, were 
still NM employees at the time of the study, and were an MD, PA, or LPN.  Based on these 
criteria, 27 qualifying clinicians were identified and recruited for participation.  Each qualifying 
clinician was contacted by e-mail, asked to participate in a 30-minute interview, and promised a 
$25 gift card for their time.  Eight clinicians agreed to participate.  All interviews were 
conducted in person, either at the clinician’s office or in a suitable conference room.  Interview 
sessions were recorded and later transcribed by a third-party transcription service.  Each 
transcript was reviewed and edited for accuracy by TMH. 
 Analysis was divided according to the structured or open-ended nature of the responses.  
All structured responses were reviewed and aggregated directly by the first author.  Unstructured 
responses (either responses to open-ended questions or elaborations upon structured responses) 
were analyzed by two independent coders to identify themes and attitudes that were not captured 
by the structured responses.  TMH performed the first coding pass and created a codebook with 
97 individual codes roughly organized in parallel with the interview guide.  This codebook, and 
un-coded copies of the transcripts, was provided to TAN, who performed a second coding pass 
without knowledge of TMH’s prior coding decisions.  TMH and TAN met in a series of sessions 
to compare coding choices and reconcile any discrepancies via one-on-one discussion.  Through 
these meetings, 100% consensus was reached without need for third-party intervention. 
 To identify the themes and axes that emerged from the coding process, we performed a 
two-pass analysis of the codebook.  TMH created physical cards individually printed with each 
code and description from the codebook and performed a card sort by grouping codes into 
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related groups.  TAN and JBS collaboratively performed a second card sort, without knowledge 
of TMH’s decisions.  The codes and categories for each pass were entered into a spreadsheet.  
All three authors jointly reviewed the results of the two passes and reconciled differences to 
finalize the overall themes used for the unstructured data analysis. 
 
Results 
Basic Demographics 
 The eight participants averaged 21.5 years of clinical experience.  Seven (87.5%) were 
board certified in only internal medicine.  One participant (12.5%) was certified in both internal 
medicine and cardiology.  On average, participants were scheduled to see patients 17 hours per 
week. 
 
Understanding Workflow 
 When presented with our model diagram representing a typical prescribing workflow, 
seven of the eight participants (87.5%) reported that they review medications earlier in their 
workflow than in the diagram.  There were no other major discrepancies between our diagram 
and actual clinician workflow.  The updated version, representing typical clinician workflow as 
reported by the participants, is presented in Figure 1.
 Figure 1 - Archetypal GIM Clinician Prescribing Workflow at NM 
A consensus, idealized prescribing workflow, as agreed upon by general internal medicine physicians at Northwestern Medicine.  
Real-world processes may include loop-backs and other variations. 
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Feedback on Existing Tools 
When asked about their thoughts on the existing PGx CDS tools, participants indicated a 
general ambivalence towards the tools, with clear room for improvement and no clear hostility 
towards the use of PGx CDS.  All eight participants (100%) reported that they recalled seeing 
PGx CDS alerts at some point in their practice.  When asked whether they felt the alerts were 
useful for them in making a prescribing decision, responses were overall neutral, with four (50%) 
finding them helpful and four (50%) not finding them helpful.  Six (75%) of the physicians had 
suggestions for improvements and two (25%) did not. 
Participants also made suggestions for improvement.  The most common suggestions 
were related to making it easier to act on the alerts.  Possible improvements included providing 
clearer guidance and specific alternative recommended medications.  This topic is explored in 
additional depth in the results of the unstructured data analysis, below. 
When asked to speculate on why real-world PGx CDS response rates for the existing 
tools are relatively low (see previous publications[13,23]), the most common response was that 
the recipient of the alert may not be the right target audience.  Six participants (75%) reported 
some variation on this idea; for instance, a different specialty may be more appropriate, or they 
may not have been the one to initiate the drug and do not want to modify it.  Five (62.5%) 
believed that it could be due to patients that are already successfully on a medication and a lack 
of desire to change what is working. 
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Appropriate Locations for PGx Information 
When asked about potential locations for presenting PGx information in the EHR, two of 
the seven options had zero participants rate them negatively on the seven-point Likert scale 
(ranging from Must Avoid to Must Have).  “As an alert during order entry, when relevant” was 
the most approved-of option, with five participants (62.5%) rating it Very Helpful and three 
(37.5%) rating it a Must Have.  “As an entry on the Problem List” also had no negative 
responses, with five participants rating it at least Helpful and three rating it Neutral.  All response 
rates are shown in Figure 2. 
  
Figure 2 – Preferences for PGx Information Location in the EHR 
Number of participants expressing level of helpfulness of seven different EHR locations for pharmacogenomic information. 
 
 
 1
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Level of Detail and Interruption for Alerts 
When asked about the level of detail and interruption an alert should provide, there was a 
general trend towards a preference for brevity in the information presented.  Additionally, 
clinicians did not want to be interrupted for alerts that were primarily informational in nature, 
although they did prefer interruption when an action was required.  The overall ranking for each 
display option was determined by the mode value.  Each queried scenario and the aggregated 
clinician-reported rankings are listed in Table 2. 
Table 2 – Preferred Level of Detail and Interruption for Alerts, by Mode Rankings 
Consensus user rankings from 1 (most preferred) through 4 (least preferred) of four different 
options for level of detail and interruption in a Pharmacogenomic Clinical Decision Support 
alert, as determined by Mode ranking; “Detailed Alert” and “Brief Alert w/ Links” are fully 
interruptive options 
 Level of Detail and Interruption 
Scenario 
Detailed 
Pop-up 
Alert 
Brief  
Pop-up 
Alert w/ 
Links 
Non-
Interruptive 
Alert No Alert 
Your patient has relevant genetic data on 
file, and that data DOES indicate a change 
from the medication or dosage you are 
selecting. 
2 1 3 4 
Your patient has relevant genetic data on 
file, but that data DOES NOT indicate a 
change from the medication or dosage you 
are selecting. 
4 3 2 1 
Your patient has relevant genetic data on 
file, but that data includes a Variant of 
Unknown Significance with no clear 
clinical impact. 
4 3 2 1 
Your patient DOES NOT have relevant 
genetic data on file, but the medication or 
dosage you are selecting has known genetic 
interactions. 
2 1 3 4 
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Types of Information to Display in Alerts 
 When asked about what type of information they prefer to see in a PGx CDS alert when a 
patient’s genetic profile indicates a medication change, participants clearly preferred two of the 
options.  The most approved-of options were “A specific recommended alternative medication 
and/or dosage,” with five participants (62.5%) rating it as a Must Have, two (25%) rating it as 
Very Helpful, and one (12.5%) rating it as Helpful and “A clinically-relevant phenotypic 
interpretation of the genetic test results (e.g., Clopidogrel Intermediate Metabolizer),” with three 
participants (37.5%) rating it as a Must Have and five (62.5%) rating it as Very Helpful.  
Conversely, “A complete, detailed description of the drug-gene interaction, and how prescribing 
is affected, taken from the academic literature” was not well-received, with three participants 
(37.5%) rating it as Very Unhelpful, three (37.5%) rating it as Neutral, and two (25%) rating it as 
Helpful.  The option “Your patient’s actual genetic data in the format returned by the testing 
laboratory (e.g., CYP2C19 *1/*17),” was also rated negatively, with two participants (25%) 
rating it as Very Unhelpful, one (12.5%) rating it as Unhelpful, two (25%) rating it as Neutral, 
and three (37.5%) rating it as Helpful.  All response rates are shown in Figure 3. 
 Figure 3 – Preferences for Types of PGx Information in Alerts 
Number of participants expressing level of helpfulness of six different types of pharmacogenomic information in clinical decision 
support alerts. 
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Trusted Knowledge Sources for PGx 
When asked where they currently turn for PGx advice, five participants (67.5%) said they 
use UpToDate, making it the most common response.  Only one participant (12.5%) was aware 
of any currently published PGx prescribing guidelines.  Six participants (75%) said they would 
trust professional societies such as American College of Physicians and American College of 
Cardiology for PGx recommendations.  Five (62.5%) said they would trust a colleague.  Only 
one participant (12.5%) was aware of CPIC prior to the interview, with seven (87.5%) being 
unfamiliar.  Despite this lack of familiarity, seven (87.5%) said they would trust CPIC 
recommendations once they were told about it.  Three participants clarified that they would trust 
CPIC recommendations, under the assumption that NM had vetted it.  Six participants (75%) 
said links to academic literature published by CPIC embedded into links would increase their 
trust in an alert’s recommendation. 
 
Emergent Themes 
 Coders reached consensus on five top-level themes with seven underlying axes when 
analyzing the open-ended responses and elaborations on structured responses.  Themes, axes, 
and common codes are presented in Table 3.  
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Table 3 – Themes, Axes, and Common Codes from Open-ended Responses 
Themes Axes 
# of Participants 
Expressing Axis 
Most Common Code 
(# of Participants) 
Attitudes and Issues 
Affecting PGx Use 
Discomfort & 
Skepticism 
8 of 8 Infrequent PGx User (8) 
Education 6 of 8 Unlikely to understand 
underlying genotypic data (2) 
Information needs reduce with 
learning effects (2) 
Affordability 6 of 8 Billing concerns/Insurance 
coverage (4) 
Clinical Relevance N/A 8 of 8 Actionable Alerts Only with 
Clear Guidance (6) 
Job Flow and System 
Design 
Burden 8 of 8 Lack of time (6) 
Workflow & 
Data Display 
8 of 8 Reviews Medications Earlier 
(7) 
Unlikely to visit another screen 
(4) 
Positive 
Receptivity to 
Alerts 
7 of 8 Potentially helpful (4) 
Level of 
Detail 
7 of 8 Include cost information (5) 
Trusted Knowledge 
Sources 
N/A 8 of 8 UpToDate 
Professional Societies 
Patient 
Communication 
N/A 3 of 8 No codes appeared more than 
once 
 
 All eight participants expressed some level of Discomfort & Skepticism in their 
responses, with the most common concept being that they are Infrequent PGx Users (8 of 8 
participants).  There was an additional trend in the Discomfort & Skepticism axis with codes that 
relate to a lack of clarity around the appropriate use of PGx information.  The following codes 
are conceptually related, and taken together, seven of eight participants expressed at least one of 
them: 
• Unsure of how to interpret (4 participants) 
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• Unsure of how to apply (2 participants) 
• Lack of clear guidance (4 participants) 
• Lack of clear alternative drugs (2 participants) 
• No clear clinical evidence (4 participants) 
• Needs clear clinical evidence (3 participants) 
• Needs to be demonstrably superior to current standards (2 participants) 
• Would use genetics when accepted standard of care (2 participants) 
• Not standard of care (1 participant) 
These expressions of uncertainty around how to interpret and apply PGx in a clear and standard 
way, along with the reported infrequent use of PGx information, demonstrates a general 
discomfort with PGx among the participants. 
 All eight participants expressed ideas that related to the Clinical Relevance of PGx alerts, 
with the most common concept being that they are interested in seeing Actionable Alerts Only 
with Clear Guidance (6 of 8 participants).  In other words, they are only interested in seeing 
alerts that they need to immediately act upon, and which contain a clear recommendation (e.g., 
“It's like, give me a clinical recommendation: ‘Pick a different statin’” [P03] and “If it does not 
interfere, I do not want to see anything” [P05]).  Other trends in this category include 6 
participants expressing that PGx was less helpful for the particular drugs in this study (generally 
because they do not use those drugs frequently, or they are declining in popularity), 5 
participants expressing some form of the idea that they were not the right audience for the alert, 5 
participants relating the usefulness of PGx to its timeliness and relevance, and 5 participants 
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expressing that PGx alerts aren’t helpful if a patient is already successful on the medication in 
question. 
 Seven participants expressed that they review a patient’s medication list early in their 
encounter process.  Four stated that they were unlikely to go to a different screen to look up 
genetic information.  Additionally, five participants expressed in some way that lists, such as 
problem lists and medication lists, are poorly maintained or inconsistent. 
 All eight participants expressed that incorporating PGx into their practice is, or could 
become, a burden on them.  Six explicitly stated that they had a Lack of Time to think about PGx 
(e.g. “In the middle of seeing 20 patients I'm not gonna go looking through that.” [P05]). 
 Despite the overall negative attitudes reported so far, seven participants expressed a 
general Positive Receptivity to Alerts.  Four explicitly stated that they think genetics-based alerts 
are potentially helpful (e.g., “I think that would be helpful if you could get it right” [P03]) and 
three expressed generally or conceptually positive attitudes about genetic data being used in 
alerts. 
Analysis of the Level of Detail axis demonstrates that highly detailed alert text is 
inappropriate.  Instead, alerts should be specific in their recommendations without too much 
detail.  Users would be willing to click links to detailed text if they feel they need it.  Three 
participants stated that they Prefer Specificity (e.g. “I just need very concrete. Like you need to 
dose ‘this’ medicine, ‘this’ often” [P01]), three stated that Details Are Too Much to Read, and 
four stated that they Would Use Detailed Links (e.g. “To actually display that information, that's 
way too much in an alert. Like a link to it will be fine” [P07]). 
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 Though participants were never asked about it explicitly, they frequently raised the issue 
of financial concerns.  Drug and genetic testing affordability were frequently cited under 
Attitudes and Issues Affecting PGx Use.  Additionally, five participants expressed a desire to see 
cost information included in alert text.  In particular, they were interested in seeing information 
about the costs of the recommended alternative drug. 
 Overall, the themes that emerged during this qualitative analysis paint a clear and 
coherent narrative.  Clinicians are receptive to the idea of using PGx in their practice, but they 
are currently uncomfortable with PGx and unclear and uneducated on how to use it.  They feel a 
sense of burden about adding it to their workflows.  They lack time to think about it, and often 
find it irrelevant.  Therefore, any interventions based on PGx must be highly actionable with 
clear, concise, and explicitly stated recommendations.  Implementers must be selective in which 
medications they build PGx alerts for and in which clinicians are exposed to them.  These results 
are concordant with the findings from the structured analysis reported above. 
Discussion 
 The high level of concordance we found in clinician preferences and attitudes allows us 
to establish a set of baseline principles upon which to build more effective PGx CDS at NM.  
Several of the findings are consistent with previous research on non-PGx CDS and the general 
concepts of being timely and relevant.[25-28] However, others are especially relevant, or even 
novel, to the use of PGx information.  We present these principles in Table 4. 
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Table 4 – Principles for More Effective PGx CDS Design 
Principle Description 
Be Specific and 
Actionable 
Make a clear recommendation to the user with a specific alternative 
medication and dosage, pre-calculated based off of the patient’s genetics.  
Avoid recommendations to simply “consider alternatives.”  Do not 
interrupt the user with informational alerts about a patient’s genetic profile 
if those test results are not immediately relevant.  Ensure the user is the 
right person to see the information.  Ensure alerts are built for the right 
medications. 
Be Brief Most physicians are not interested in reading in-depth information on 
genetics at the point of care, so keep text brief and simple.  Make 
educational materials available through a link for those that want more 
background. 
Display 
Phenotypes not 
Genotypes 
Because most physicians are generally not well trained on genetics, they do 
not find raw genetic data useful in an alert.  Avoid values like “CYP2C19 
*2/*2,” and instead provide a phenotypic interpretation such as 
“Clopidogrel Poor Metabolizer.” 
Rely on Sources 
Clinicians 
Already Trust 
Because genetics-based prescribing is novel to many clinicians, lean on 
sources they already trust, whenever possible.  Use information from 
UpToDate, established professional societies, or emphasize that your 
institution has vetted the recommendations coming from unfamiliar 
sources. 
Be Adaptable to 
Learning Effects 
As physicians learn and become more comfortable with PGx, their 
information needs may change over time. Review and revise alert designs 
on a regular basis or design them to be adaptable in the content they 
display. 
 
In Table 5, we compare these principles to prior work in the literature.  The Devine, et al., 
Nishimura, et al., and Melton, et al. works represent prior evaluations of PGx CDS systems that 
attempted to extrapolate one or more recommendations for alert design from user testing.  
Nishimura, et al. and Melton, et al. were limited in their attempts to provide broad design 
recommendations but drew conclusions similar to our “Be Brief” and “Be Specific and 
Actionable” principles.  Our results largely concur with the results of the work by Devine, et al., 
but with the addition of our “Be Adaptable to Learning Effects” principle.  The Horsky, et al. 
study is a systematic review of traditional (non-PGx) CDS systems that draws from 112 articles.  
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Of relevance to PGx CDS, they concur with our recommendations around brevity and trust.  
Their analysis is silent on the topic of genotype and phenotype, as well as on potential learning 
effects.  While they touch on the concepts of specificity and actionability, they draw somewhat 
different conclusions than us.  They recommend CDS that is more “advisory,” because “some 
clinicians may perceive overly prescriptive advice [as] infringing on their sense of professional 
autonomy.”  Though we do not recommend PGx CDS alerts be wholly inflexible and 
commanding in their design, we do find that, likely due to lack of education on the topic, 
participants in this study preferred stronger, more specific recommendations and showed distaste 
for more ambiguous or unspecific guidance. 
 
Table 5 – PGx CDS Design Principles in the Literature 
 
A comparison of the PGx CDS design principles established in this study to design principles 
established in prior Non-PGx CDS and PGx CDS system evaluations.  (Symbol definitions: x = 
full concurrence between this study and the cited study; * = partial concurrence between this 
study and the cited study) 
 Prior Studies 
 Non-PGx PGx CDS 
Principle Horsky 
[26] 
Devine 
[29] 
Nishimura 
[30] 
Melton 
[31] 
Be Specific and Actionable * x 
 
x 
Be Brief x x x 
 
Display Phenotypes not Genotypes 
 
x 
  
Rely on Sources Clinicians Already Trust x x 
  
Be Adaptable to Learning Effects 
    
 
This comparison begins to shed light on the question of how PGx CDS may be different 
from other forms of CDS.  Clearly, the need for abstraction from genotype to phenotype is 
unique to the PGx space.  Additionally, the need to account for learning effects is likely novel 
because most other forms of CDS convey information clinicians are likely to have already been 
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formally trained on.  Finally, we find evidence in favor of stronger recommendations that rely 
less on clinician autonomy and are unambiguous about the expected alternative action. 
Based on the results of this study, the issue of passive PGx alerting (i.e., optional to view, 
as opposed to interruptive) deserves particular attention.  Of the seven location choices provided, 
“in an alert on a separate Best Practice Advisories tab in the patient’s chart” was the least 
popular option among clinicians, due to the fact that many users do not regularly check that 
location in the EHR.  This result suggests that passive alerting may not be the most effective 
approach.  However, previous work at NM shows that even infrequent use leads to a significant 
number of actual alert interactions, due to sheer volume.  Passive alerts should not be discounted 
because their default location is unpopular, but it is a good idea to reconsider where such alerts 
should appear.  Our results suggest that another location that is already part of common 
workflows may be more appropriate, such as the Problem List or Medications List.  In the future, 
as genetic data use becomes more common, a Genetic Information section may also be 
appropriate.  These solutions will require PGx data standards and EHR support that either do not 
currently exist or are only in the earliest stages of functionality. 
Two particular findings of this study concur with previous PGx literature.  The general 
sentiments of uncertainty and doubt expressed by the clinicians we interviewed are consistent 
with previous publications documenting the low level of physician education in 
pharmacogenomics.[3] Additionally, our finding that clinicians hold a generally neutral view of 
PGx’s helpfulness, with some receptivity to its use in the future, is consistent with our previous 
findings.[23] Given the time difference between when those attitudes were assessed (2015 vs. 
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2019), it does not appear that those attitudes are changing quickly at NM; nor have those 
attitudes been altered with further exposure to the first-generation PGx CDS tools at NM. 
Our finding that PGx CDS recommendations need to be specific and actionable is at odds 
with the current state of PGx guidelines.   Currently, the closest the field has to a “gold standard” 
for PGx CDS is the genetically-based prescribing recommendations published by CPIC.[7] 
These recommendations are very useful for identifying when a drug-gene interaction is relevant 
and when to interrupt the clinician, but they do not go so far as to provide a specific 
recommended alternative.  Therefore, PGx CDS that directly translates CPIC recommendations 
in their published form is unlikely to be well received by clinicians.  Organizations such as CPIC 
should strive to provide more specific recommendations in the future, but that will take 
significant time to achieve, due to the complexities of the decision-making process.  Genetics are 
only one piece of the equation, with other patient-specific clinical factors being highly relevant.  
Until the field develops comprehensive algorithms for calculating recommended medications and 
dosages based off of both genetics and traditional clinical variables, it will likely fall upon 
individual institutions to create and implement their own rules and recommendations.  This will 
require substantial institutional commitment and will likely lead to further heterogeneity of 
practice. 
In light of these results, we reiterate the need for standardized PGx interpretations and 
vocabularies, which we, and others, have called for in previous publications.[13,32,33] 
Phenotypic interpretations are clearly a critical component of conveying PGx knowledge to 
clinicians and standardized terms would significantly ease future implementations and EHR 
support.  Additionally, computable vocabularies for representing this information in EHRs will 
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be necessary for integrating PGx information deeply into the clinician workflow outside of just 
pop-up alerts (e.g., Problem and Medication List support, and Genetic Information screens). 
Finally, in recognition of the fact that most currently-practicing clinicians have not been 
trained in PGx,[3] we would call upon the sources that clinicians most trust, such as professional 
societies like the American College of Physicians and American College of Cardiologists, and 
reference providers like UpToDate, to seriously examine and expand upon the use of PGx data in 
their guidelines and best practices, when appropriate.  Particularly in light of recently issued 
FDA guidance for CDS, it is critical that there be established clinical guidelines that PGx CDS 
systems can cite in their recommendations.[34] 
 
Conclusion 
Through the use of socio-technical principles, this study demonstrates areas in which 
PGx CDS is different from traditional CDS and provides direction for future PGx CDS designs.  
Unlike traditional CDS, PGx CDS requires abstraction of clinical data through the use of 
phenotypes rather than genotypes.  Additionally, lack of training means that recommendations 
must be clear and strong and that there are likely learning effects to account for.  Clinicians 
showed a preference for brief alerts that are clear about the expected action with specific 
alternative recommended medications and dosages.  They also frequently expressed feelings of 
uncertainty and doubt around the use of PGx, so future designs must focus on simplicity and 
specificity while referencing well-trusted sources.  Designs following these principles are more 
likely to encourage adherence than those that simply provide information for the clinician to 
consider on their own.  Therefore, current CPIC PGx recommendations do not directly translate 
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to successful CDS because they do not provide specific recommendations.  Until specific 
recommendations become more standardized, any institution interested in using PGx CDS must 
commit to establishing recommended alternatives.  Likewise, the field as a whole must work to 
develop standardized phenotypic interpretations and vocabularies for clinically relevant PGx 
results. 
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